Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Non Hodgkin Lymphoma (NHL) Market?

In recent times, there has been a substantial growth in the market size of non hodgkin lymphoma (NHL). The market, which is worth $10.11 billion as of 2024, is projected to increase to $11.01 billion in 2025, with a compound annual growth rate (CAGR) of 8.9%. This upsurge during the historical period can be credited to factors such as the heightened incidence of NHL, progress in diagnostic procedures, advancements in chemotherapy and immunotherapy, enhanced emphasis on clinical research and drug development, as well as improved survival rates.

What Growth Rate Is Forecasted for the Non Hodgkin Lymphoma (NHL) Market by 2029?

The market for non-hodgkin lymphoma (NHL) is predicted to experience substantial growth in the coming years, reaching an estimated value of “$15.42 billion by 2029, reflecting a compound annual growth rate (CAGR) of 8.8%. Factors such as an aging population, development in targeted treatments, breakthroughs in immunotherapy, precision medicine methodologies, and increased consciousness and early screening are contributing to this predicted growth. The prediction period also sees a surge in biosimilars, the inclusion of next-generation sequencing, the use of car-t cell therapies, new chemotherapy agents, as well as real-world evidence and outcomes study.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10676&type=smp

Which Key Companies Are Shaping the Future of the Non Hodgkin Lymphoma (NHL) Market?

Major companies operating in the non hodgkin lymphoma (NHL) market include Bayer AG, Teva Pharmaceutical Industries Ltd., F. Hoffmann La Roche Ltd., Merck & Co. Inc., Eli Lilly and Co., Novartis AG, GlaxoSmithKline plc, AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb Co., Pfizer Inc., Celgene Corporation, Sanofi S.A., Janssen Pharmaceuticals Inc., Johnson & Johnson, Biogen Idec, Boehringer Ingelheim GmbH, Eisai Co. Ltd., Gilead Sciences, Incyte Corporation, Karyopharm Therapeutics, Kite Pharma Inc., Kyowa Hakko Kirin Co. Ltd., MorphoSys AG, Nordic Nanovector ASA, Ono Pharmaceutical Co. Ltd., Seattle Genetics Inc., Spectrum Pharmaceuticals Inc.

Which Factors Are Driving Demand in the Non Hodgkin Lymphoma (NHL) Industry?

The high incidence of non-Hodgkin lymphoma in the population is predicted to fuel the expansion of the non-Hodgkin lymphoma market. Non-Hodgkin lymphoma, a cancer of the lymphatic system—an essential component of the immune system—has a high occurrence, signifying a significant number of people living with or diagnosed with the disease at any given time. Targeted treatments for non-Hodgkin lymphoma can enhance the prognosis for those currently diagnosed by managing the cancerous cells. The American Cancer Society, a medical organization based in the US, reported in January 2023 that non-Hodgkin lymphoma was responsible for 4% of all cancer cases. In 2023, it is projected that approximately 80,550 Americans, comprising 44,880 males and 35,670 females, will be affected. It further estimates that non-Hodgkin lymphoma will lead to the death of 20,180 people in 2023. In addition, as per the Canadian Cancer Society, a charity organization in Canada, 11,400 Canadians were diagnosed with non-Hodgkin lymphoma in May 2022, and it’s calculated to cause 3,000 deaths in 2022. Thus, the large occurrence of non-Hodgkin lymphoma is a major contributor to the growth of the non-Hodgkin lymphoma market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10676&type=smp

How Is the Non Hodgkin Lymphoma (NHL) Market Segmented by Several Divisions?

The non hodgkin lymphoma (NHL) market covered in this report is segmented –

1) By Type: B-Cell Lymphoma, T-Cell Lymphoma

2) By Treatment: Surgery, Stem Cell Transplant, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy

3) By Route of Administration: Oral, Parenteral, Other Routes of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Homecare, Specialty Centers, Other End Users

Subsegments:

1) By B-Cell Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphoma, Primary Mediastinal B-Cell Lymphoma

2) By T-Cell Lymphoma: Peripheral T-Cell Lymphoma (PTCL), Anaplastic Large Cell Lymphoma (ALCL), Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoblastic Lymphoma, Adult T-Cell Leukemia/Lymphoma (ATLL)

What are the Emerging Market Trends Driving the Growth of the Non Hodgkin Lymphoma (NHL) Industry?

The rise of drug innovations is a significant trend that’s becoming increasingly prevalent in the non-Hodgkin lymphoma market. Companies in this market are concentrated on producing new products to maintain their market standing. For example, in December 2022, Genentech Inc., a biotechnology firm based in the United States, got FDA authorization for Lunsumio, a groundbreaking bispecific antibody designed to treat relapsed or refractory follicular lymphoma. This antibody represents a new type of fixed-duration cancer treatment immunotherapy, and it’s a readily available, off-the-shelf treatment that patients can receive without delay. The FDA gave its approval based on positive results from the Phase II GO29781 study of Lunsumio in patients heavily pretreated for FL, especially those at a high risk of disease progression or non-responsive to previous treatments.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Which Regions Are Driving Growth in the Non Hodgkin Lymphoma (NHL) Market?

North America was the largest region in the non-Hodgkin lymphoma (NHL) market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global non-Hodgkin lymphoma (NHL) market report during the forecast period. The regions covered in the non-Hodgkin lymphoma (NHL) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10676

This Report Delivers Insight On:

1. How big is the non hodgkin lymphoma (nhl) market, and how is it changing globally?

2. Who are the major companies in the non hodgkin lymphoma (nhl) market, and how are they performing?

3. What are the key opportunities and risks in the non hodgkin lymphoma (nhl) market right now?

4. Which products or customer segments are growing the most in the non hodgkin lymphoma (nhl) market?

5. What factors are helping or slowing down the growth of the non hodgkin lymphoma (nhl) market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model